Cerebrospinal Fluid Levels of Autophagy-related Proteins Represent Potentially Novel Biomarkers of Early-Stage Parkinson’s Disease

[1]  K. Kakudo,et al.  Cetuximab-resistant oral squamous cell carcinoma cells become sensitive in anchorage-independent culture conditions through the activation of the EGFR/AKT pathway. , 2015, International journal of oncology.

[2]  Kenichiro Tanaka,et al.  The utility of the combined use of 123I-FP-CIT SPECT and neuromelanin MRI in differentiating Parkinson's disease from other parkinsonian syndromes , 2019, Acta radiologica.

[3]  Y. Compta,et al.  Cerebrospinal fluid levels of alpha-synuclein in PARKINSON'S disease: Another long and winding road. , 2018, Parkinsonism & related disorders.

[4]  P. Calabresi,et al.  Diagnostic utility of cerebrospinal fluid α‐synuclein in Parkinson's disease: A systematic review and meta‐analysis , 2017, Movement disorders : official journal of the Movement Disorder Society.

[5]  S. Ito,et al.  Usefulness of combining 123I-FP-CIT-SPECT striatal asymmetry index and cardiac 123I-metaiodobenzylguanidine scintigraphy examinations for diagnosis of parkinsonisms , 2017, Journal of the Neurological Sciences.

[6]  J. Gramsbergen,et al.  Cerebrospinal fluid biomarkers for Parkinson's disease – a systematic review , 2017, Acta neurologica Scandinavica.

[7]  D. Klionsky,et al.  Autophagy: machinery and regulation , 2016, Microbial cell.

[8]  K. Blennow,et al.  Cerebrospinal fluid biomarkers in Alzheimer's and Parkinson's diseases—From pathophysiology to clinical practice , 2016, Movement disorders : official journal of the Movement Disorder Society.

[9]  P. Svenningsson,et al.  Distinct Lysosomal Network Protein Profiles in Parkinsonian Syndrome Cerebrospinal Fluid , 2016, Journal of Parkinson's disease.

[10]  K. Blennow,et al.  Longitudinal Measurements of Cerebrospinal Fluid Biomarkers in Parkinson's Disease , 2016, Movement disorders : official journal of the Movement Disorder Society.

[11]  Ying Peng,et al.  Autophagy biomarkers in CSF correlates with infarct size, clinical severity and neurological outcome in AIS patients , 2015, Journal of Translational Medicine.

[12]  G. Halliday,et al.  Lysosomal‐associated membrane protein 2 isoforms are differentially affected in early Parkinson's disease , 2015, Movement disorders : official journal of the Movement Disorder Society.

[13]  Suneil K. Kalia,et al.  Disease‐modifying strategies for Parkinson's disease , 2015, Movement disorders : official journal of the Movement Disorder Society.

[14]  J. O'Callaghan,et al.  Biomarkers of Parkinson's disease: present and future. , 2015, Metabolism: clinical and experimental.

[15]  P. Stanzione,et al.  Do CSF levels of t-Tau, p-Tau and β1-42 amyloid correlate with dopaminergic system impairment in patients with a clinical diagnosis of Parkinson disease? A 123I-FP-CIT study in the early stages of the disease , 2014, European Journal of Nuclear Medicine and Molecular Imaging.

[16]  Jin-Tai Yu,et al.  Autophagy in aging and neurodegenerative diseases: implications for pathogenesis and therapy , 2014, Neurobiology of Aging.

[17]  A. Lees,et al.  Cerebrospinal fluid biomarkers in parkinsonian conditions: an update and future directions , 2014, Journal of Neurology, Neurosurgery & Psychiatry.

[18]  P. Calabresi,et al.  Differential role of CSF alpha-synuclein species, tau, and Aβ42 in Parkinson's Disease , 2014, Front. Aging Neurosci..

[19]  H. Berendse,et al.  Reduced α‐synuclein levels in cerebrospinal fluid in Parkinson's disease are unrelated to clinical and imaging measures of disease severity , 2014, European journal of neurology.

[20]  Joong-Seok Kim,et al.  Safety and efficacy of recombinant human erythropoietin treatment of non-motor symptoms in Parkinson's disease , 2014, Journal of the Neurological Sciences.

[21]  K. Blennow,et al.  Lysosomal Network Proteins as Potential Novel CSF Biomarkers for Alzheimer’s Disease , 2013, NeuroMolecular Medicine.

[22]  Arthur W Toga,et al.  Association of cerebrospinal fluid β-amyloid 1-42, T-tau, P-tau181, and α-synuclein levels with clinical features of drug-naive patients with early Parkinson disease. , 2013, JAMA neurology.

[23]  M. Mcdermott,et al.  Longitudinal assessment of tau and amyloid beta in cerebrospinal fluid of Parkinson disease , 2013, Acta Neuropathologica.

[24]  P. Calabresi,et al.  Cerebrospinal fluid biomarkers in Parkinson disease , 2013, Nature Reviews Neurology.

[25]  S. Chung,et al.  Validation of the Korean-Version of the Nonmotor Symptoms Scale for Parkinson's Disease , 2012, Journal of clinical neurology.

[26]  B. Hyman,et al.  Alpha-synuclein aggregation involves a bafilomycin A1-sensitive autophagy pathway , 2012, Autophagy.

[27]  D. Klionsky,et al.  The role of autophagy in Parkinson's disease. , 2012, Cold Spring Harbor perspectives in medicine.

[28]  Dae Hyuk Moon,et al.  Subregional Patterns of Preferential Striatal Dopamine Transporter Loss Differ in Parkinson Disease, Progressive Supranuclear Palsy, and Multiple-System Atrophy , 2012, The Journal of Nuclear Medicine.

[29]  D. Mann,et al.  Post mortem cerebrospinal fluid α-synuclein levels are raised in multiple system atrophy and distinguish this from the other α-synucleinopathies, Parkinson's disease and Dementia with Lewy bodies , 2012, Neurobiology of Disease.

[30]  P. Calabresi,et al.  Cerebrospinal fluid Tau/α‐synuclein ratio in Parkinson's disease and degenerative dementias , 2011, Movement disorders : official journal of the Movement Disorder Society.

[31]  E. Waxman,et al.  Induction of Intracellular Tau Aggregation Is Promoted by α-Synuclein Seeds and Provides Novel Insights into the Hyperphosphorylation of Tau , 2011, The Journal of Neuroscience.

[32]  Valeria Dibilio,et al.  Single Photon Emission Computed Tomography Striatal Asymmetry Index May Predict Dopaminergic Responsiveness in Parkinson Disease , 2011, Clinical neuropharmacology.

[33]  P. Hluštík,et al.  CSF markers of neurodegeneration in Parkinson’s disease , 2010, Journal of Neural Transmission.

[34]  K. Blennow,et al.  CSF amyloid-β and tau proteins, and cognitive performance, in early and untreated Parkinson's Disease: the Norwegian ParkWest study , 2010, Journal of Neurology, Neurosurgery & Psychiatry.

[35]  Koen Van Laere,et al.  EANM procedure guidelines for brain neurotransmission SPECT using 123I-labelled dopamine transporter ligands, version 2 , 2010, European Journal of Nuclear Medicine and Molecular Imaging.

[36]  J. Fleming,et al.  A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking , 2009, Neurology.

[37]  Duk L. Na,et al.  Brief Screening for Mild Cognitive Impairment in Elderly Outpatient Clinic: Validation of the Korean Version of the Montreal Cognitive Assessment , 2008, Journal of geriatric psychiatry and neurology.

[38]  P. Calabresi,et al.  Lysosomal hydrolases in cerebrospinal fluid from subjects with Parkinson's disease , 2007, Movement disorders : official journal of the Movement Disorder Society.

[39]  S. Ryu,et al.  Usefulness of Beck Depression Inventory (BDI) in the Korean elderly population , 2007, International journal of geriatric psychiatry.

[40]  T. Tokuda,et al.  Decreased α-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson’s disease. , 2006 .

[41]  Peter T. Lansbury,et al.  Impaired Degradation of Mutant α-Synuclein by Chaperone-Mediated Autophagy , 2004, Science.

[42]  He-Jin Lee,et al.  Clearance of α-Synuclein Oligomeric Intermediates via the Lysosomal Degradation Pathway , 2004, The Journal of Neuroscience.

[43]  S L Wolf,et al.  Modified Emory Functional Ambulation Profile: An Outcome Measure for the Rehabilitation of Poststroke Gait Dysfunction , 2001, Stroke.

[44]  D. DeMets,et al.  Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework , 2001, Clinical pharmacology and therapeutics.

[45]  M. Hoehn,et al.  Parkinsonism , 1998, Neurology.

[46]  M. Hoehn,et al.  Parkinsonism , 1967, Neurology.

[47]  K. Chaudhuri,et al.  Non-motor symptoms profile and burden in drug naïve versus long-term Parkinson's disease patients. , 2014, Journal of Parkinson's disease.

[48]  Simon C Watkins,et al.  Regulation of autophagy by extracellular signal-regulated protein kinases during 1-methyl-4-phenylpyridinium-induced cell death. , 2007, The American journal of pathology.

[49]  T. Tokuda,et al.  Decreased alpha-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson's disease. , 2006, Biochemical and biophysical research communications.

[50]  He-Jin Lee,et al.  Clearance of alpha-synuclein oligomeric intermediates via the lysosomal degradation pathway. , 2004, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[51]  Leonidas Stefanis,et al.  Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy. , 2004, Science.

[52]  John A. Martin,et al.  Convergence of Lewy bodies and neurofibrillary tangles in amygdala neurons of Alzheimer’s disease and Lewy body disorders , 1996, Acta Neuropathologica.